Company Overview of Zambon Company S.p.A.
Zambon Company S.p.A. manufactures and delivers fine chemical and pharmaceutical products for customers in Italy and internationally. The company offers respiratory solutions comprising medical devices for children and adults breath wellness, and children and family breath protection products; pain management products; women healthcare products that include solutions in the area of urinary pathologies; and Xadago (safinamide) for Parkinson's disease treatment. Its fine chemical products comprise custom synthesis, generics APIs, and generics FDF Dossiers. Zambon Company S.p.A. was founded in 1906 and is based in Bresso, Italy with additional offices in Europe, Asia, and South America. It has ...
Via Lillo del Duca, 10
Bresso, MI 20091
Founded in 1906
Key Executives for Zambon Company S.p.A.
Vice President of Business Development
Compensation as of Fiscal Year 2017.
Zambon Company S.p.A. Key Developments
Zambon Company S.p.A. Presents at BIO International Conference 2017, Jun-21-2017 03:45 PM
May 27 17
Zambon Company S.p.A. Presents at BIO International Conference 2017, Jun-21-2017 03:45 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Cibele Sabido, Head of Business Development CNS and Other Therapeutic Areas.
Zambon and Newron Pharmaceuticals Launch Parkinson's Disease Treatment Xadago in Portugal
Apr 12 17
Zambon and its compatriot partner Newron Pharmaceuticals have announced the launch in Portugal of their Parkinson's disease (PD) treatment Xadago (safinamide). The drug has been approved as an add-on to levodopa alone or in combination with other PD drugs for treating patients with mid- to late-stage PD.
Valeo Pharma Inc. and Zambon S.p.A Form Partnership for Parkinson's Disease Treatment Xadago in Canada
Apr 11 17
Zambon S.p.A. and Valeo Pharma Inc. announced a strategic agreement to commercialize Xadago (safinamide) for the treatment of Parkinson's disease in Canada. Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada. Valeo Pharma will pay Zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries